Add to ORKGOrphan drugs: challenges for economic evaluation • Public-private partnerships for health and development Pharmaceutical pricing in France • Parallel trade and cost control • Access to medicines in sub-Saharan Africa Pricing pharmaceuticals Generic medicines: savings to health care systems? Innovation and regulation in the pharmaceutical sector Pharmaceutical policy: cost containment and its impac
The reimbursement of drugs that treat rare diseases, also known as orphan drugs, have been the topic...
Context. Recent public outcry has highlighted the rising cost of prescription drugs worldwide, which...
The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spai
Biotechnology Industry Organization, corporate social responsibility, extraordinary pricing, Nationa...
In the pharmaceutical field, the term ‘fourth hurdle ’ hasbecome common currency in many health syst...
Orphan drugs (OD) require considerable expenditures, which causes difficulties in their market acces...
The business model under which the pharmaceutical industry has operated in the recent past has becom...
Generic medicines offer equally high-quality treatment as originator medicines do at much lower pric...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
Master in Health Economics and Pharmacoeconomics (UPF Barcelona School of Management) Curs 2018-2021...
Abstract Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, ...
There had been increased and strong public interests in rare diseases and orphan drugs as well as th...
International audienceBackground:Drug development for rare diseases has been limited mainly by the p...
Context. Recent public outcry has highlighted the rising cost of prescription drugs worldwide, which...
While the safety and availability of medicinal products for the majority of adult patients has stead...
The reimbursement of drugs that treat rare diseases, also known as orphan drugs, have been the topic...
Context. Recent public outcry has highlighted the rising cost of prescription drugs worldwide, which...
The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spai
Biotechnology Industry Organization, corporate social responsibility, extraordinary pricing, Nationa...
In the pharmaceutical field, the term ‘fourth hurdle ’ hasbecome common currency in many health syst...
Orphan drugs (OD) require considerable expenditures, which causes difficulties in their market acces...
The business model under which the pharmaceutical industry has operated in the recent past has becom...
Generic medicines offer equally high-quality treatment as originator medicines do at much lower pric...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
Master in Health Economics and Pharmacoeconomics (UPF Barcelona School of Management) Curs 2018-2021...
Abstract Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, ...
There had been increased and strong public interests in rare diseases and orphan drugs as well as th...
International audienceBackground:Drug development for rare diseases has been limited mainly by the p...
Context. Recent public outcry has highlighted the rising cost of prescription drugs worldwide, which...
While the safety and availability of medicinal products for the majority of adult patients has stead...
The reimbursement of drugs that treat rare diseases, also known as orphan drugs, have been the topic...
Context. Recent public outcry has highlighted the rising cost of prescription drugs worldwide, which...
The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spai
